<DOC>
	<DOCNO>NCT02672592</DOCNO>
	<brief_summary>Obesity metabolic syndrome men associate high prevalence hypogonadism 50 % . Increased fat mass lead augmented release adipocytokines pro-inflammatory cytokine IL-1-beta , IL-6 tumor necrosis factor-alpha turn suppress hypothalamic-pituitary-gonadal ( HPG ) axis , lead hypogonadism . This pathophysiological interplay term hypogonadal-obesity-adipocytokine hypothesis . TestIL prospective , multicenter , randomize , double-blinded , placebo-controlled trial test hypothesis inhibition IL-1-activity diminishes inhibitory effect HPG axis increase testosterone level men metabolic syndrome .</brief_summary>
	<brief_title>Effects Interleukin-1 Beta Low Testosterone Levels Men With Obesity Metabolic Syndrome</brief_title>
	<detailed_description>Obesity metabolic syndrome consider chronic low-grade inflammatory state . Elevated pro-inflammatory mediator obesity metabolic syndrome inhibitory effect hypothalamic-pituitary-gonadal axis ( HPG axis ) lead hypogonadism . Decreased testosterone production obese men turn promote additional fat deposition , contribute vicious cycle fat accumulation . This complex pathophysiological interplay term hypogonadal-obesity-adipocytokine hypothesis , describe bidirectional relationship low level testosterone metabolic syndrome . TestIL prospective , multicenter , randomize , double-blinded , placebo-controlled trial test hypothesis inhibition IL-1-activity diminishes inhibitory effect HPG axis increase testosterone level men metabolic syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<criteria>1 . Informed consent document signature , 2 . Men age 18 75 year , 3 . BMI &gt; 30 kg/m2 least 1 manifestation metabolic syndrome ( i.e . prediabetes , diabetes , hypertension , dyslipidemia ) , 4 . Total testosterone level &lt; 12 nmol/l . 1 . Previous current medication testosterone , 2 . Testosterone deficiency cause , i.e . primary hypogonadism cause e.g . Klinefelters syndrome , cryptorchidism , condition follow orchiectomy . Known secondary hypogonadism cause pituitary adenoma . Patients antiandrogen medication , 3 . Clinical sign infection week inclusion history severe infection last 2 month , 4 . Severe immunosuppression ( e.g . patient previously know infection human immunodeficiency virus cluster differentiation 4 ( CD4 ) count 350 x 109/L , patient immunosuppressive therapy solid organ transplantation neutropenic patient neutrophil count &lt; 500 x 109/L patient chemotherapy neutrophils 5001000 x 109/L expect decrease value &lt; 500 x 109/L ) , 5 . Hematologic disease ( leukocyte count &lt; 1.5 x 109/l , hemoglobin &lt; 11 g/dl , platelet &lt; 100 x 103/µl ) , 6 . Other clinically significant concomitant disease state ( e.g. , renal failure [ CreatinineClearance &lt; 30 ml/min ] , hepatic dysfunction [ transaminases &gt; 3x upper normal range ] , active carcinoma , 7 . History tuberculosis , 8 . Known suspected noncompliance , drug alcohol abuse , 9 . Contraindications class drug study , e.g . know hypersensitivity allergy anakinra/Kineret® , 10 . Inability follow procedure study , e.g . due language problem , psychological disorder , dementia , etc . participant , 11 . Previous enrolment current study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metabolic syndrome X</keyword>
	<keyword>Hypogonadism</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Obesity</keyword>
</DOC>